For instance, the combination of endothelin 1 (ET-1) antagonist ambrisentan and phosphodiesterase 5 (PDE-5) inhibitor tadalafil is considered the gold standard for most patients with PAH [5]. This evidence concerns the gene EDN1 and pulmonary arterial hypertension.